Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1828 1
1874 1
1880 2
1893 2
1911 1
1950 1
1953 2
1954 2
1957 1
1958 1
1959 2
1960 2
1961 8
1962 8
1963 4
1964 3
1965 2
1966 9
1967 11
1968 6
1969 9
1970 4
1971 6
1972 9
1973 6
1974 17
1975 16
1976 13
1977 15
1978 19
1979 19
1980 13
1981 18
1982 20
1983 16
1984 17
1985 18
1986 27
1987 19
1988 20
1989 18
1990 16
1991 24
1992 21
1993 28
1994 43
1995 37
1996 24
1997 24
1998 28
1999 27
2000 36
2001 49
2002 39
2003 58
2004 44
2005 50
2006 42
2007 41
2008 64
2009 79
2010 87
2011 89
2012 85
2013 87
2014 95
2015 102
2016 104
2017 104
2018 111
2019 94
2020 119
2021 119
2022 120
2023 117
2024 114
2025 130
2026 34

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,627 results

Results by year

Filters applied: . Clear all
Page 1
Oxidised IL-33 drives COPD epithelial pathogenesis via ST2-independent RAGE/EGFR signalling complex.
Strickson S, Houslay KF, Negri VA, Ohne Y, Ottosson T, Dodd RB, Huntington CC, Baker T, Li J, Stephenson KE, O'Connor AJ, Sagawe JS, Killick H, Moore T, Rees DG, Koch S, Sanden C, Wang Y, Gubbins E, Ghaedi M, Kolbeck R, Saumyaa S, Erjefält JS, Sims GP, Humbles AA, Scott IC, Romero Ros X, Cohen ES. Strickson S, et al. Among authors: baker t. Eur Respir J. 2023 Sep 28;62(3):2202210. doi: 10.1183/13993003.02210-2022. Print 2023 Sep. Eur Respir J. 2023. PMID: 37442582 Free PMC article.
Interferon subverts an AHR-JUN axis to promote CXCL13+ T cells in lupus.
Law C, Wacleche VS, Cao Y, Pillai A, Sowerby J, Hancock B, Horisberger A, Bracero S, Skidanova V, Li Z, Adejoorin I, Dillon E, Benque IJ, Nunez DP, Simmons DP, Keegan J, Chen L, Baker T, Brohawn PZ, Al-Mossawi H, Hao LY, Jones B, Rao N, Qu Y, Alves SE; Accelerating Medicines Partnership: RA/SLE Network; Jonsson AH, Shaw KS, Vleugels RA, Massarotti E, Costenbader KH, Brenner MB, Lederer JA, Hultquist JF, Choi J, Rao DA. Law C, et al. Among authors: baker t. Nature. 2024 Jul;631(8022):857-866. doi: 10.1038/s41586-024-07627-2. Epub 2024 Jul 10. Nature. 2024. PMID: 38987586 Free PMC article.
Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials.
Baker T, Sharifian H, Newcombe PJ, Gavin PG, Lazarus MN, Ramaswamy M, White WI, Ferrari N, Muthas D, Tummala R, Morand EF, Furie RA, Vital EM, Chamberlain C, Platt A, Al-Mossawi H, Brohawn PZ, Csomor E. Baker T, et al. Ann Rheum Dis. 2024 Jul 15;83(8):1018-1027. doi: 10.1136/ard-2023-225445. Ann Rheum Dis. 2024. PMID: 38569851 Free PMC article. Clinical Trial.
Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths.
HEALing Communities Study Consortium; Samet JH, El-Bassel N, Winhusen TJ, Jackson RD, Oga EA, Chandler RK, Villani J, Freisthler B, Adams J, Aldridge A, Angerame A, Babineau DC, Bagley SM, Baker TJ, Balvanz P, Barbosa C, Barocas J, Battaglia TA, Beard DD, Beers D, Blevins D, Bove N, Bridden C, Brown JL, Bush HM, Bush JL, Caldwell R, Calver K, Calvert D, Campbell ANC, Carpenter J, Caspar R, Chassler D, Chaya J, Cheng DM, Cunningham CO, Dasgupta A, David JL, Davis A, Dean T, Drainoni ML, Eggleston B, Fanucchi LC, Feaster DJ, Fernandez S, Figueroa W, Freedman DA, Freeman PR, Freiermuth CE, Friedlander E, Gelberg KH, Gibson EB, Gilbert L, Glasgow L, Goddard-Eckrich DA, Gomori S, Gruss DE, Gulley J, Gutnick D, Hall ME, Harger Dykes N, Hargrove SL, Harlow K, Harris A, Harris D, Helme DW, Holloway J, Hotchkiss J, Huang T, Huerta TR, Hunt T, Hyder A, Ingram VL, Ingram T, Kauffman E, Kimball JL, Kinnard EN, Knott C, Knudsen HK, Konstan MW, Kosakowski S, Larochelle MR, Leaver HM, LeBaron PA, Lefebvre RC, Levin FR, Lewis N, Lewis N, Lofwall MR, Lounsbury DW, Luster JE, Lyons MS, Mack A, Marks KR, Marquesano S, Mauk R, McAlearney AS, McConnell K, McGladrey ML, McMullan J, Miles J, Muno… See abstract for full author list ➔ HEALing Communities Study Consortium, et al. Among authors: baker tj. N Engl J Med. 2024 Sep 19;391(11):989-1001. doi: 10.1056/NEJMoa2401177. Epub 2024 Jun 16. N Engl J Med. 2024. PMID: 38884347 Free PMC article. Clinical Trial.
Opportunities and insights from pharmaceutical companies on the current use of new approach methodologies in nonclinical safety assessment.
Shenton J, Bousnina I, Oropallo M, David R, Weir L, Baker TK, Dunmore HM, Villenave R, McElroy M, Pettersen B, Kokate T, Fuller CL, Homan KA, Hudry E, Wood C, Gunter S. Shenton J, et al. Among authors: baker tk. Drug Discov Today. 2025 Apr;30(4):104328. doi: 10.1016/j.drudis.2025.104328. Epub 2025 Mar 12. Drug Discov Today. 2025. PMID: 40086787 Free article. Review.
2,627 results